# A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

> **NCT05363605** · PHASE1,PHASE2 · TERMINATED · sponsor: **Fusion Pharmaceuticals Inc.** · enrollment: 6 (actual)

## Conditions studied

- Advanced Solid Tumor
- Head and Neck Squamous Cell Carcinoma
- Bladder Carcinoma
- Susceptible FGFR3 Genetic Alterations
- FGFR3
- FGFR3 Overexpression
- FGFR3 Receptor
- FGFR3 Protein Overexpression
- Ovarian Cancer
- Colorectal Cancer
- Breast Cancer
- Liver Cancer
- Lung Cancer
- Gastric Cancer

## Interventions

- **DRUG:** [225Ac]-FPI-1966
- **DRUG:** [111In]-FPI-1967
- **BIOLOGICAL:** vofatamab

## Key facts

- **NCT ID:** NCT05363605
- **Lead sponsor:** Fusion Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-20
- **Primary completion:** 2023-09-08
- **Final completion:** 2023-09-08
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Fusion announced that it is discontinuing this study as part of a portfolio prioritization and assessment; Fusion no longer plans to pursue development of FPI-1966.
- **Last updated:** 2023-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05363605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05363605, "A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05363605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*